knowledge -WSS

knowledge

author：focus 2025-08-30 11:02:12 - browse：3

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： New weight loss drugs work. But how can they best be used?

leisure time

WSS

Ahead of JPM, here's who's profiting most in health care

What the Wegovy shortage looks like for doctors — and for patients

Female surgeons have lower rates of long

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Akero's treatment for NASH falls short in cirrhosis study

STAT Readout Newsletter: Today in biotech, life science news

explore

knowledge

leisure time

23andMe had bad news about my health. I wish a person had delivered it

How doctors and nurses shape Google's AI

At least 13 dead in Texas as scorching temps continue

Antibiotic resistance and the global rise in human conflict

Affirmative action in medical school literally saved lives

Why psychiatrists like me stop taking insurance

Continuity nursing helped my family in our darkest PICU moments

STAT Readout: Today's biotech news includes Sana and Amylyx

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AdventHealth escalates lawsuit against insurance vendor Multiplan

entertainment

White House finalizes ITC's import ban of latest Apple Watches

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

White House finalizes ITC's import ban of latest Apple Watches

Readout LOUD podcast: Merger Mondays, Ozempic panic

European regulators consider appeal over Amylyx ALS drug

What the Wegovy shortage looks like for doctors — and for patients

focus

leisure time

entertainment

hotspot